Avacta AVA6103 clears clinical mechanism hurdle as 2027 efficacy test moves into focus

Avacta Group plc (AIM: AVCT) has achieved an important early clinical milestone for AVA6103 after preliminary Phase 1 FOCUS-01 data showed its next-generation preCISION drug-delivery system behaving in patients broadly as predicted by preclinical modelling. The first 19 patients have completed treatment across the initial three dose levels, including an exatecan payload dose of 4.5 mg/m² that Avacta said is approximately 50% higher than the published maximum tolerated dose of conventional exatecan. Early safety findings remained sufficiently encouraging for the company to continue dose escalation, while pharmacokinetic data indicated prolonged controlled release of exatecan following administration. The development strengthens evidence that Avacta’s controlled-release technology can function in humans, but the much more consequential question of whether that mechanism translates into meaningful and durable tumor responses will not begin to be answered until efficacy data arrive in the first half of 2027.

AVA6103, also known as FAP-Exd, combines Avacta’s fibroblast activation protein-targeting preCISION technology with exatecan, a potent topoisomerase I inhibitor. The therapeutic concept is intended to expose tumors to cytotoxic drug while reducing the systemic exposure that can restrict conventional chemotherapy dosing. Avacta’s September 16 update therefore goes beyond a routine dose-escalation announcement because AVA6103 represents the first clinical test of the controlled-release generation of preCISION, following earlier work with first-generation candidate AVA6000.

The initial three dose levels were 1.5 mg/m², 3 mg/m² and 4.5 mg/m², administered across separate every-two-week and every-three-week dosing arms. Avacta said screening is continuing for both arms at dose level four, indicating that the early safety findings have not prevented further escalation. The Phase 1 study is enrolling patients with advanced solid tumors including colorectal cancer, pancreatic ductal adenocarcinoma, gastric and gastroesophageal junction cancers, cervical cancer and small-cell lung cancer.

Why does AVA6103 tolerability above conventional exatecan exposure matter for Avacta?

The most immediately measurable feature of the initial AVA6103 dataset is the relationship between dose and toxicity. Avacta reported no neutropenia among the first 19 treated patients, while thrombocytopenia occurred in one patient, anemia in three patients and nausea or vomiting in one patient. At the highest of the first three dose levels, the administered exatecan payload was approximately 50% above the maximum tolerated dose reported for conventional exatecan in an earlier Phase 1 study.

Avacta compared those observations with historical published studies involving conventional exatecan and the antibody-drug conjugate Enhertu, which releases the related topoisomerase I inhibitor deruxtecan. The company cited neutropenia rates of 22% at similar Enhertu payload doses and 64% at the conventional exatecan maximum tolerated dose, compared with none so far in the AVA6103 population. Thrombocytopenia was reported in 5% of AVA6103 patients, compared with 11% in the referenced Enhertu dataset and 43% with conventional exatecan, while nausea and vomiting were also less frequent in the initial AVA6103 cohorts.

Those comparisons are informative but need careful interpretation because they come from different trials, patient populations, dosing schedules and treatment eras rather than from a randomized head-to-head clinical study. The stronger conclusion supported by the data is that AVA6103 has so far allowed Avacta to escalate exatecan payload exposure without encountering toxicity sufficient to halt the program at the first three dose levels. Continued dose escalation will show whether that therapeutic window can expand further or whether toxicity becomes more prominent as exposure increases.

A wider therapeutic window could become commercially meaningful if it allows tumors to receive greater or more sustained exposure to a potent cytotoxic payload than would be practical through conventional systemic administration. Higher dose alone would not guarantee better efficacy, particularly across biologically different tumor types, but it could give Avacta more room to optimize exposure during the remainder of FOCUS-01.

How do the AVA6103 pharmacokinetic results strengthen the controlled-release preCISION thesis?

The pharmacokinetic findings are arguably more important to Avacta’s platform strategy than the initial safety percentages because they test whether the engineered delivery mechanism is operating in humans as intended. Avacta reported a rapid reduction in circulating intact AVA6103 after dosing, followed by prolonged low-level detection of products generated when the molecule is cleaved, including released exatecan and the preCISION peptide. The company said the clinical profiles across the first three dose levels showed close alignment with pharmacokinetic modelling developed from preclinical studies.

Avacta also detected low concentrations of released peptide in plasma for as long as 48 hours after dosing. Because previous work with AVA6000 indicated that the released peptide has a short half-life of roughly two to three hours, Avacta interprets its continued detection as evidence that AVA6103 is being retained in tumor tissue and progressively cleaved over time. In the company’s model, the tumor effectively acts as a drug reservoir that gradually releases exatecan rather than allowing a large amount of active payload to circulate systemically immediately after administration.

That interpretation still requires additional confirmation. Avacta plans to obtain clinical tumor-biopsy data that could directly test whether AVA6103 is accumulating and being retained within tumors in the manner suggested by the plasma pharmacokinetics. Those biopsy findings are expected alongside initial efficacy data during the first half of 2027.

The value of successful confirmation would extend beyond AVA6103. Avacta is developing preCISION as a repeatable delivery architecture capable of carrying different cytotoxic payloads, meaning reliable translation between preclinical modelling and clinical pharmacokinetics could reduce some development uncertainty for subsequent candidates. AVA6103 therefore functions simultaneously as an experimental cancer medicine and as a human validation exercise for the company’s second-generation technology.

What does Avacta’s Enhertu comparison really show and what remains unproven?

Avacta also disclosed a preclinical head-to-head experiment comparing AVA6103 with Enhertu, the AstraZeneca and Daiichi Sankyo antibody-drug conjugate that targets HER2. In a HER2-positive, FAP-positive gastric cancer patient-derived xenograft model, the company reported that AVA6103 produced deep and prolonged partial responses in all six treated animals using its dose-dense regimen. Enhertu slowed tumor growth in the comparator group, with two animals showing small tumor reductions and one of six recording progression as best response, according to Avacta.

The result provides supportive evidence for AVA6103’s development, particularly because antibody-drug conjugates such as Enhertu have demonstrated the commercial and therapeutic potential of targeted cytotoxic delivery. It does not establish clinical superiority over Enhertu. AVA6103 and Enhertu use different targeting mechanisms, and the comparison was conducted in an animal model rather than in a randomized trial involving patients.

The more useful strategic interpretation is that Avacta is testing whether FAP-mediated tumor activation can become an alternative delivery architecture to antibody-based targeting. Antibody-drug conjugates generally rely on expression of a specific tumor-associated antigen, while Avacta’s approach is designed around FAP in the tumor microenvironment. If clinical efficacy eventually supports that mechanism across multiple tumor settings, preCISION could offer a different route for delivering established cytotoxic payloads without requiring the same antigen-targeting structure as conventional antibody-drug conjugates.

That possibility remains several clinical steps away from validation. The 2027 efficacy data will need to show that the favorable pharmacokinetic and tolerability characteristics seen so far produce measurable patient benefit rather than simply permitting higher drug exposure.

How does AVA6103 change the evidence supporting Avacta’s wider oncology pipeline?

Avacta entered 2026 with more than one preCISION generation moving through development, making AVA6103 particularly relevant to the credibility of the wider platform. First-generation faridoxorubicin, or AVA6000, has already provided human evidence around tumor-activated delivery of doxorubicin, while AVA6103 adds a controlled-release mechanism and a different cytotoxic payload. Third-generation AVA6207 is being designed around dual-payload delivery, potentially allowing two anticancer agents to be targeted through the same broader technology architecture.

The United States Food and Drug Administration has already agreed with Avacta on the design of a potential pivotal study for AVA6000 in salivary gland cancer, with progression-free survival planned as the primary endpoint. Avacta has also reported encouraging early efficacy observations from the AVA6000 program and said health authorities removed the conventional lifetime maximum doxorubicin dose restriction in its study following the cardiac-safety evidence generated to date.

AVA6103 consequently adds an important second strand of human evidence. If two chemically different payloads can be delivered using successive generations of the same FAP-activated approach, Avacta gains more evidence that preCISION is a platform rather than technology dependent on one particular drug. That distinction could matter in partnership discussions because pharmaceutical companies evaluating a delivery technology generally need evidence of reproducibility before assigning substantial value to applications beyond the lead asset.

Management has said discussions are continuing with multiple potential partners across first, second and third-generation preCISION assets. The September AVA6103 findings strengthen the dataset available in those discussions, although partnering remains a prospective commercial opportunity rather than contracted revenue. Human efficacy data would substantially increase the amount of clinical evidence counterparties can use when assessing the platform.

Why is the first half of 2027 becoming the critical AVA6103 clinical window?

Avacta expects the first efficacy data from FOCUS-01 during the first half of 2027, together with clinical tumor-biopsy findings. Those results should move the investment debate from whether AVA6103 behaves mechanistically as designed toward whether the pharmacology produces meaningful anticancer activity in humans. Response depth, durability, disease control, dose-response relationships and variation between tumor types will all become more relevant once sufficient patients have been treated.

Before then, Avacta plans to present trial-design and preclinical information at the American Association for Cancer Research pancreatic cancer conference from September 25 to September 28 and at the European Society for Medical Oncology Congress in October. The company also expects to present information supporting clinical candidate selection for its dual-payload AVA6207 program during the fourth quarter of 2026, alongside additional clinical data from AVA6000.

This creates a sequence of catalysts rather than dependence on a single announcement. AVA6000 provides evidence for first-generation delivery, AVA6103 is now testing controlled release in humans, and AVA6207 could establish how the technology develops into multi-payload constructs. The stronger these datasets become collectively, the easier it becomes to evaluate whether Avacta owns a scalable oncology-delivery platform rather than a collection of independent experimental assets.

How does Avacta’s funding position affect its ability to reach the next clinical milestones?

Clinical progress remains closely linked to financing because Avacta is still funding multiple development programs before generating mature recurring product revenue. The company reported cash and short-term deposits of £16.9 million at the end of 2025 and cash of £16.4 million at April 30, 2026. A £10 million equity financing completed in March extended the company’s stated cash runway into early first-quarter 2027.

Avacta followed that financing with an approximately £9 million institutional and shareholder placing in June, primarily intended to support repayments under its convertible bond. By June, the company said it had secured £41.5 million in gross equity proceeds over the preceding 18 months, giving management additional flexibility while clinical programs progressed.

The company has subsequently reduced its convertible debt further. On September 4, Avacta announced a £2.613 million cash payment covering £2.4 million of principal plus associated interest and fees on a deferred quarterly repayment. After that settlement and its July scheduled payment, Avacta said outstanding convertible bond principal had been reduced to £12 million.

That improvement in the capital structure does not remove future funding considerations. With AVA6103, AVA6000 and AVA6207 all moving through development, Avacta will continue balancing clinical expenditure, debt obligations and the timing of potential partnering income. Successful efficacy data or a meaningful licensing agreement could increase financing flexibility, while clinical delays would potentially extend the period over which the company must fund development internally or through additional capital.

What does the recent AVCT share-price reaction say about investor expectations?

Avacta shares closed at 76 pence on September 17, giving the company a market capitalization of roughly £356 million based on market data available after the latest completed session. The shares had risen from 68.9 pence on September 10 to 80 pence on September 15 ahead of the AVA6103 announcement, then traded as high as 88 pence intraday on September 16 before closing at 78.6 pence. The stock subsequently closed September 17 at 76 pence.

Trading volume rose sharply around the clinical announcement, with approximately 7.7 million shares changing hands on September 16 compared with materially lower volumes across many earlier September sessions. The combination of higher turnover, an intraday rise and a weaker close suggests considerable interest in the clinical milestone but not an unqualified repricing of the company around the initial mechanism data.

The stock remained about 15.6% higher over one month through September 17 and around 33% higher in 2026, while its quoted 52-week range stood at approximately 48 pence to 92 pence. That performance indicates strengthening sentiment around the clinical pipeline, but AVCT remained below its recent 52-week high after the AVA6103 announcement.

The market response fits the stage of the program. Mechanistic validation can reduce scientific uncertainty, particularly for a platform company, but investors still have to assign considerable uncertainty to clinical efficacy, development timelines, funding requirements and eventual commercialization. A stronger and more durable rerating would therefore likely require evidence that the favorable AVA6103 pharmacology produces meaningful patient responses or that pharmaceutical partners are prepared to commit capital to the technology.

What evidence would turn AVA6103 proof of mechanism into broader preCISION validation?

The September results materially advance AVA6103 because the controlled-release pharmacokinetic profile predicted from preclinical research is now visible in patients and dose escalation has continued beyond conventional exatecan exposure without the toxicity profile that might have stopped development earlier. For Avacta, that is an important reduction in mechanism risk, particularly because AVA6103 is the first human test of the second-generation controlled-release preCISION design.

The evidence required from here is more demanding. Tumor biopsies need to support the proposed drug-reservoir mechanism, dose escalation must identify an appropriate development regimen, and the first efficacy dataset needs to show that patients are receiving a therapeutic benefit consistent with the improved delivery profile. Results will also need to establish whether activity is concentrated in particular tumor types or can extend across the wider FAP-rich solid-tumor opportunity Avacta is targeting.

If those pieces begin to align in 2027, AVA6103 could do more than advance as an individual oncology candidate. It could provide human evidence that Avacta can repeatedly use preCISION to change the delivery characteristics of potent cytotoxic drugs, strengthening the rationale for AVA6207 and potential future licensed payloads. If meaningful efficacy fails to emerge despite favorable pharmacokinetics, the September mechanism data would remain scientifically interesting but would carry much less commercial significance.

The next measurable proof point is therefore clear: Avacta has shown that AVA6103 can behave approximately as designed in the bloodstream while dose escalation continues. The first-half 2027 efficacy and tumor-biopsy data will test whether that engineered pharmacology produces the tumor exposure and clinical responses required to turn preCISION from a promising delivery concept into a more broadly validated oncology platform.

Key takeaways from Avacta AVA6103 Phase 1 FOCUS-01 clinical data

• Avacta has reported clinical proof of mechanism for AVA6103 after treating 19 patients across the first three Phase 1 dose levels.
• AVA6103 reached an exatecan payload dose of 4.5 mg/m², about 50% above the published maximum tolerated dose of conventional exatecan cited by Avacta.
• Early toxicity remained limited enough for enrollment and dose escalation to continue at dose level four.
• Pharmacokinetic data closely tracked Avacta’s preclinical modelling and showed prolonged controlled release following administration.
• Detection of released peptide for as long as 48 hours supports Avacta’s proposed tumor-reservoir mechanism, although tumor biopsies are still required for direct clinical confirmation.
• The company’s favorable comparison with Enhertu was generated in a preclinical animal model and does not demonstrate clinical superiority.
• AVA6103 strengthens the evidence base behind preCISION alongside first-generation AVA6000 and planned dual-payload candidate AVA6207.
• Avacta had reduced remaining convertible bond principal to £12 million by early September while continuing to finance several clinical programs.
• AVCT closed at 76 pence on September 17 after reaching an intraday high of 88 pence when the AVA6103 announcement was released a day earlier.
• Initial AVA6103 efficacy and tumor-biopsy data expected in the first half of 2027 represent the next major test of the platform.